BIIB

Biogen Inc. NMS · BIIB

$197.74 -5.42 (-2.67%)

Pullback · -0.54σ

+ Compare Open in Sniper

Mkt cap $29.2B

P/E 21.3

Day $197.40 – $204.30

52wk $168.64 – $219.72

Avg vol 1.3M

Beta 0.16

Div yld —

Next earnings 2026-07-29

Quick read

At a glance

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally.

BIIB last traded at $197.74, down 2.7% on the day; that's in the middle part of its 52-week range ($168.64–$219.72). Right now it's dipped below its recent average — a spot where watchers often look for signs the dip is stabilizing.

The next scheduled earnings report (2026-07-29) is the biggest known catalyst on the calendar, and after the recent dip, watch whether the price stops making lower lows before assuming the worst is over.

A quick snapshot built from the data on this page — not investment advice. Always do your own research.

Today's read

Grading desk →

Price is sitting close to its normal range — not meaningfully overheated yet. Plus a bearish engulfing candle — selling fully swallowed the prior bar's buying.

Long —

Setup score 12 / 100

Price is sitting close to its normal range — no real dip to buy yet.

· Aligned with weak uptrend

Technical read: above KC1 lower, -0.58 ATR from EMA21 · no notable pattern

What it means: Price is sitting close to its normal range — no real dip to buy yet. The trigger bar shows no standout candle signal yet.

Score split: chart signals 12 / 80 · news & fundamentals checks 0 / 20 — chart signals carry most of the grade.

How this grade was earned

total 12 pts

Cycle position 6

Market fit 6

Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.

Short —

Setup score 22 / 100

Price is sitting close to its normal range — not meaningfully overheated yet. bearish engulfing candle.

· Bearish engulfing — body fully covers prior green bar

Technical read: below KC1 upper, -0.58 ATR from EMA21 · bearish engulfing

What it means: Price is sitting close to its normal range — not meaningfully overheated yet. The trigger bar shows a bearish engulfing candle — selling fully swallowed the prior bar's buying.

Score split: chart signals 22 / 80 · news & fundamentals checks 0 / 20 — chart signals carry most of the grade.

How this grade was earned

total 22 pts

Cycle position 6

Candle signal 13

Market fit 3

Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.

132-Day Trend Zones

Full chart →

21 EMA +1 ATR +2 ATR −2 ATR

—

O — H — L — C —

— —

Valuation & accounting

Valuation desk →

Our cash-flow model pegs fair value near $175.90 (fair range $167–$272); today's price sits 17% above that estimate. The model's verdict is “Overvalued” and accounting quality screens as Adequate. Model estimates only — do your own due diligence.

Overvalued -17% margin of safety Accounting: Adequate

Intrinsic (DCF)

$175.90

Fair-value range

$167.22 – $272.26

Margin of safety

-17%

Accounting quality Adequate

✓ Quick ratio 1.84 (antifragile)
✓ Current ratio 2.68 (antifragile)
✓ Debt/equity 0.61 (antifragile)
✓ Positive retained earnings

⚠ Debt exceeds cash

Price implies ~4% growth (vs trailing rev yoy). Model estimate — do your own due diligence.

Key statistics

All statistics →

BIIB is a $29.2 billion company, priced at 21× last year's earnings, and it moves more calmly than the market (beta 0.2).

Market cap $29.2B

P/E ttm 21.3

Beta 0.16

52w range $168.64 – $219.72

Avg volume 1.3M

Dividend yield —

Sector Healthcare

Next earnings 2026-07-29

52-week range · today's price

$168.64$219.72

More on BIIB

Options idea

See more →

CALL $200 2026-08-21

$17.72

PUT $195 2026-08-21

$7.00

Earnings

See more →

Last reported: 2026-04-29
EPS (act / est): 3.57 / 2.89
Surprise: +23.6%
Next report: 2026-07-29

About

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to t…